Percheron Therapeutics Limited
PERCF
$0.0025
-$0.0165-86.84%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 49.04% | 45.35% | -- |
| Total Other Revenue | -87.34% | -87.05% | -139.93% | -134.05% | 141.12% |
| Total Revenue | -87.34% | -87.05% | 18.56% | 15.63% | 141.12% |
| Cost of Revenue | 122.70% | 129.08% | 36.96% | 34.04% | 123.81% |
| Gross Profit | -95.20% | -95.09% | 18.39% | 15.46% | 141.82% |
| SG&A Expenses | 33.97% | 37.09% | 63.57% | 59.54% | 3.37% |
| Depreciation & Amortization | -23.38% | -21.94% | -33.33% | -35.58% | -1.28% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 44.99% | 48.37% | 16.28% | 13.42% | 2.18% |
| Operating Income | -78.50% | -82.68% | -15.75% | -12.88% | 10.83% |
| Income Before Tax | -79.94% | -84.14% | -15.92% | -13.06% | 10.87% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -79.94% | -84.14% | -15.92% | -13.06% | 10.87% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -79.94% | -84.14% | -15.92% | -13.06% | 10.87% |
| EBIT | -78.50% | -82.68% | -15.75% | -12.88% | 10.83% |
| EBITDA | -79.54% | -83.73% | -15.78% | -12.93% | 11.63% |
| EPS Basic | -42.86% | -47.62% | 23.33% | 25.81% | 19.23% |
| Normalized Basic EPS | -46.15% | -46.15% | 26.32% | 30.00% | 18.75% |
| EPS Diluted | -36.36% | -40.91% | 23.33% | 25.81% | 15.38% |
| Normalized Diluted EPS | -46.15% | -46.15% | 26.32% | 30.00% | 18.75% |
| Average Basic Shares Outstanding | 28.70% | 28.70% | 55.22% | 55.22% | 8.26% |
| Average Diluted Shares Outstanding | 28.70% | 28.70% | 55.22% | 55.22% | 8.26% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |